AU2020263283B2 - Cyclic phosphate compounds - Google Patents

Cyclic phosphate compounds

Info

Publication number
AU2020263283B2
AU2020263283B2 AU2020263283A AU2020263283A AU2020263283B2 AU 2020263283 B2 AU2020263283 B2 AU 2020263283B2 AU 2020263283 A AU2020263283 A AU 2020263283A AU 2020263283 A AU2020263283 A AU 2020263283A AU 2020263283 B2 AU2020263283 B2 AU 2020263283B2
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
alkyl
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020263283A
Other languages
English (en)
Other versions
AU2020263283A1 (en
Inventor
Lin Zhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Publication of AU2020263283A1 publication Critical patent/AU2020263283A1/en
Application granted granted Critical
Publication of AU2020263283B2 publication Critical patent/AU2020263283B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020263283A 2019-04-22 2020-04-21 Cyclic phosphate compounds Active AU2020263283B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837137P 2019-04-22 2019-04-22
US62/837,137 2019-04-22
PCT/US2020/029149 WO2020219464A1 (en) 2019-04-22 2020-04-21 Cyclic phosphate compounds

Publications (2)

Publication Number Publication Date
AU2020263283A1 AU2020263283A1 (en) 2021-12-16
AU2020263283B2 true AU2020263283B2 (en) 2026-04-23

Family

ID=72941350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020263283A Active AU2020263283B2 (en) 2019-04-22 2020-04-21 Cyclic phosphate compounds

Country Status (9)

Country Link
US (1) US20220220145A1 (https=)
EP (1) EP3966221A4 (https=)
JP (2) JP7661235B2 (https=)
KR (1) KR20210154229A (https=)
CN (1) CN113939526A (https=)
AU (1) AU2020263283B2 (https=)
CA (1) CA3136954A1 (https=)
MX (1) MX2021012894A (https=)
WO (1) WO2020219464A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
JP2023523415A (ja) * 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
WO2021216431A1 (en) * 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Benzyloxy phosph(on)ate compounds
EP4232456A4 (en) * 2020-10-21 2026-04-01 Ligand Pharm Inc COMPOUNDS OF ANTIVIRAL MEDICINES
WO2022245584A1 (en) * 2021-05-17 2022-11-24 Ligand Pharmaceuticals Incorporated Unnatural configuration nucleotide prodrug compounds
CN118005694B (zh) * 2023-01-06 2025-04-22 北京双鹤润创科技有限公司 一种环状核苷类似物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026786A1 (en) * 1996-12-19 1998-06-25 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
WO2007027248A2 (en) * 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
WO2013177195A1 (en) * 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2014058801A1 (en) * 2012-10-08 2014-04-17 Idenix Pharmaceuticals, Inc. 2'-chloro nucleoside analogs for hcv infection
WO2015161137A1 (en) * 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2017223012A1 (en) * 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023120B2 (ja) * 1979-08-13 1985-06-05 キッコーマン株式会社 アデノシン−３′，５′−環状リン酸アルキルトリエステルの製造法
DE3027279A1 (de) * 1980-07-18 1982-05-06 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5834436A (en) * 1993-04-09 1998-11-10 The Regents Of The University Of California Membrane-permeant second messengers
US5693521A (en) * 1993-04-09 1997-12-02 The Regents Of The University Of California Membrane-permeant second messengers
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2819041A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
JP2016501200A (ja) * 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ウイルス性疾患を処置するための２−アルキニル置換ヌクレオシド誘導体
BR112015014457A2 (pt) * 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
EP3661513A4 (en) 2017-07-31 2021-07-14 January Therapeutics, Inc. ORGANOPHOSPHATE DERIVATIVES
CN111801339B (zh) 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
US20210038628A1 (en) * 2018-03-02 2021-02-11 January Therapeutics, Inc. Nanoparticle compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026786A1 (en) * 1996-12-19 1998-06-25 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
WO2007027248A2 (en) * 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
WO2013177195A1 (en) * 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2014058801A1 (en) * 2012-10-08 2014-04-17 Idenix Pharmaceuticals, Inc. 2'-chloro nucleoside analogs for hcv infection
WO2015161137A1 (en) * 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2017223012A1 (en) * 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bartsch, M. et al, "Bioactivatable, membrane-permeant analogs of cyclic nucleotides as biological tools for growth control of C6 glioma cells", Biological Chemistry (2003), 384(9), 1321-1326 *
Broeders, Niek L. H. L. et al, "Conformational transmission in pentacoordinated phosphorus systems, modeling the activated state of cyclic AMP", Heteroatom Chemistry (1991), 2(1), 205-11 *
Chepurny, O. G. et al, "Enhanced Rap1 Activation and Insulin Secretagogue Properties of an Acetoxymethyl Ester of an Epac-selective Cyclic AMP Analog in Rat INS-1 Cells", J Biol Chem 2009, 284(16), 10728-10736 *
Dittmar, Fanni et al, "Regulation of apoptosis by cyclic nucleotides in human erythroleukemia (HEL) cells and human myelogenous leukemia (K-562) cells", Biochemical Pharmacology (2016), 112, 13-23 *
Kruppa, J. et al, "Bioactivatable derivatives of 8-substituted cAMP analogs", Bioorganic & Medicinal Chemistry Letters (1997), 7(7), 945-948 *
Li, Jiajia et al, "Activation of the Small GTPase Rap1 Inhibits Choroidal Neovascularization by Regulating Cell Junctions and ROS Generation in Rats", Current Eye Research (2018), 43(7), 934-940 *
Schwede, F. et al, "Membrane-permeant, bio-activatable analogs of cGMP as inducers of cell death in IPC-81 leukemia cells", Bioorganic & Medicinal Chemistry Letters (2000), 10(6), 571-573 *

Also Published As

Publication number Publication date
JP7661235B2 (ja) 2025-04-14
AU2020263283A1 (en) 2021-12-16
EP3966221A1 (en) 2022-03-16
WO2020219464A1 (en) 2020-10-29
US20220220145A1 (en) 2022-07-14
KR20210154229A (ko) 2021-12-20
JP2025106352A (ja) 2025-07-15
CA3136954A1 (en) 2020-10-29
EP3966221A4 (en) 2023-05-24
JP2022529321A (ja) 2022-06-21
MX2021012894A (es) 2021-11-17
CN113939526A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
AU2020263283B2 (en) Cyclic phosphate compounds
WO2019143860A1 (en) 5-fluorouracil compounds
EP4143199B1 (en) Nucleotide prodrug compounds
US10435429B2 (en) 5-fluorouridine monophosphate cyclic triester compounds
WO2022086958A1 (en) Antiviral prodrug compounds
EP4335496A2 (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US20240425542A1 (en) Cyclic deoxyribonucleotide compounds
JP2026032020A (ja) ベンジルオキシリン酸エステル（ホスホン酸エステル）化合物
AU2020315394B2 (en) Cyclic deoxyribonucleotide compounds
RU2836016C2 (ru) Циклические дезоксирибонуклеотидные соединения
US20250188111A1 (en) Cyclic phosphoramidate compounds
HK40108726A (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
KR20260062967A (ko) 사이클릭 포스페이트 화합물
HK40063264A (en) Cyclic deoxyribonucleotide compounds